Filtered By:
Source: Diabetes, Obesity and Metabolism

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 82 results found since Jan 2013.

Patient Empowerment Programme in primary care reduced all‐cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population‐based propensity‐matched cohort study
ConclusionsEnrolment in the PEP was associated with lower all‐cause mortality and a lower number of first CVD events among patients with T2DM. The CVD benefit of PEP might be attributable to improving metabolic control through empowerment of self‐care and the enhancement of quality of diabetes care in primary care.
Source: Diabetes, Obesity and Metabolism - October 20, 2014 Category: Endocrinology Authors: C. K. H. Wong, W. C. W. Wong, Y. F. Wan, A. K. C. Chan, K. L. Chung, F. W. K. Chan, C. L. K. Lam Tags: ORIGINAL ARTICLE Source Type: research

Patient Empowerment Programme (PEP) in Primary Care Reduced All‐cause Mortality and Cardiovascular Diseases in Patients with Type 2 Diabetes Mellitus: A Population‐based Propensity Matched Cohort Study
ConclusionsEnrolment in PEP was associated with reduced all‐cause mortality and first CVD events among T2DM patients. The CVD benefit of PEP might be attributable to improving metabolic control through empowerment of self‐care and enhancement of quality of diabetes care in primary care.
Source: Diabetes, Obesity and Metabolism - September 23, 2014 Category: Endocrinology Authors: Carlos K.H. Wong, William C.W. Wong, Y.F. Wan, Anca K.C. Chan, K.L. Chung, Frank W.K. Chan, Cindy L.K. Lam Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower CV risk in type 2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - June 9, 2014 Category: Endocrinology Authors: U. M. Mogensen, C. Andersson, E. L. Fosbøl, T. K. Schramm, A. Vaag, N. M. Scheller, C. Torp‐Pedersen, G. Gislason, L. Køber Tags: ORIGINAL ARTICLE Source Type: research

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality
ConclusionsThere was a reduction in all‐cause mortality for patients treated with metformin combined with DPP‐4i versus metformin plus SU, and a similar trend for MACE.
Source: Diabetes, Obesity and Metabolism - May 22, 2014 Category: Endocrinology Authors: C. Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S. E. Holden, C. J. Currie Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower cardiovascular risk in type‐2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - May 14, 2014 Category: Endocrinology Authors: Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp‐Pedersen, Gunnar Gislason, Lars Køber Tags: ORIGINAL PAPER Source Type: research

Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study
ConclusionsAll‐cause mortality was significantly increased in patients prescribed sulphonylurea compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that first‐line treatment with sulphonylurea monotherapy should be reconsidered.
Source: Diabetes, Obesity and Metabolism - May 8, 2014 Category: Endocrinology Authors: C. Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S. E. Holden, C. J. Currie Tags: ORIGINAL ARTICLE Source Type: research

Combination therapy with metformin plus sulfonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality
ConclusionsThere was a reduction in all‐cause mortality for patients treated with metformin combined with DPP‐4i versus metformin plus SU, and a similar trend for MACE.
Source: Diabetes, Obesity and Metabolism - April 25, 2014 Category: Endocrinology Authors: C.Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S.E. Holden, C. J. Currie Tags: Original Paper Source Type: research

Association between first‐line monotherapy with sulfonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study
ConclusionsAll‐cause mortality was significantly increased in patients prescribed sulfonylurea compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that first‐line treatment with sulfonylurea monotherapy should be reconsidered.
Source: Diabetes, Obesity and Metabolism - April 1, 2014 Category: Endocrinology Authors: C.Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S.E. Holden, C.J. Currie Tags: ORIGINAL PAPER Source Type: research

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
ConclusionsOn the basis of simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - February 19, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman, M. Cohen Tags: ORIGINAL ARTICLE Source Type: research

Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes
ConclusionsBased on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - January 20, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H.L. Grossman, M. Cohen Tags: Original Paper Source Type: research

The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Abstract The glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exenatide and liraglutide have been shown to improve glycaemic control and beta‐cell function with a low risk of hypoglycaemia in people with type 2 diabetes. GLP‐1 receptors are also expressed in extra‐pancreatic tissues and trial data suggest GLP‐1RAs also have effects beyond their glycaemic actions. Preclinical studies using native GLP‐1 or GLP‐1RAs provide substantial evidence for cardioprotective effects, while clinical trial data have demonstrated beneficial actions on hypertension and dyslipidaemia in people with type 2 diabetes. Sig...
Source: Diabetes, Obesity and Metabolism - December 24, 2013 Category: Endocrinology Authors: J Seufert, B Gallwitz Tags: Unsolicited Review Article Source Type: research

Gender‐specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - December 5, 2013 Category: Endocrinology Authors: G. E. C. Sun, B. J. Wells, K. Yip, R. Zimmerman, D. Raghavan, M. W. Kattan, S. R. Kashyap Tags: ORIGINAL ARTICLE Source Type: research

Gender‐Specific Effects of Oral Hypoglycemic Agents on Cancer Risk in Type 2 Diabetes Mellitus
ConclusionsOral insulin sensitizers, particularly thiazolidinedione, are associated with decreased malignancy risk in women with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - November 6, 2013 Category: Endocrinology Authors: Grace E. Ching Sun, Brian J. Wells, Kathleen Yip, Robert Zimmerman, Derek Raghavan, Michael W. Kattan, Sangeeta R. Kashyap Tags: Original Paper Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - September 10, 2013 Category: Endocrinology Authors: N. M. Scheller, U. M. Mogensen, C. Andersson, A. Vaag, C. Torp‐Pedersen Tags: ORIGINAL ARTICLE Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research